Mani D.R., Krug K., Zhang B., Satpathy S. et al. Cancer proteogenomics: current impact and future prospects, Nature Reviews Cancer, 2020.
Satpathy S*, Krug K*, Beltran JMP*, Savage S*, et al. A proteogenomic portrait of lung squamous cell carcinoma, Cell, 2021. DOI: 10.1016/j.cell.2021.07.016. * co-first authorship
Krug K*, Jaehnig EJ* ,Satpathy S* et.al. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy, Cell, 2020, * co-first authorship
Gillette MA*, Satpathy S*, Cao S, et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020 Jul 9;182(1):200-225.e35. *Equal contribution
Satpathy S, Jaehnig EJ, Krug K, et al. Microscaled proteogenomic methods for precision oncology. Nat Comm. 2020 Jan 27;11(1):532.
Udeshi ND, Mani DC, Satpathy S et al. Rapid and deep-scale ubiquitylation profiling for biology and translational research. Nat Comm. 2020 Jan 17;11(1):359.
Weiner BT, Narita T, Satpathy S, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018 Jun 28;174(1):231-244.e12. D
Satpathy S, Wagner SA, Beli P, et al. Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation. Mol Syst Biol. 2015 Jun 2;11(6):810.
Shankha Satpathy, Ph.D.
Shankha Satpathy is a senior group leader and research scientist in the Proteomics Platform at the Broad Institute of MIT and Harvard. As part of the proteomics group at Broad, he is involved in several proteomics technology development areas, and also contributes to academic- and industry-partnered collaborative projects using mass spectrometry and other proteomic tools to investigate interesting biological questions with potential translational impact. His work intersects multiple disciplines and involves both basic scientists and clinicians. He is a key member of the CPTAC consortium and leads several clinical proteomics and proteogenomic projects. Of note was the development of a proteogenomics workflow for core-needle biopsy and its application in a range of solid tumor clinical trials, and the comprehensive proteogenomic characterization of breast cancer, lung adenocarcinoma, and lung squamous cell carcinoma that Satpathy co-led with research groups within the CPTAC consortium.
Satpathy joined the Broad in September 2017 as a postdoctoral associate in the laboratory of Steven Carr. He has been a staff scientist since 2019, and is a senior group leader in proteomics since 2022. He conducted his doctoral research in the application of proteomics to decipher immune signaling pathways, at the Novo Nordisk Foundation Center for Protein Research in Copenhagen and earned his Ph.D. from the University of Copenhagen in 2017. He also holds a M.S. in biochemistry and molecular biology from the Cumming School of Medicine, University of Calgary and a B.Tech. in biotechnology from Vellore Institute of Technology, India.
As part of the Broad, he loves working in a fast paced and collaborative environment surrounded by motivated and inspiring colleagues.
Contact Shankha Satpathy via email at firstname.lastname@example.org.